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BACKGROUND: Accurate gestational dating is a critical component of and linear discriminate analyses to create a linear function for PTB and to
obstetric and newborn care. In the absence of early ultrasound, many
clinicians rely on less accurate measures, such as last menstrual period or
symphysis-fundal height during pregnancy, or Dubowitz scoring or the
Ballard (or New Ballard) method at birth. These measures often under-
estimate or overestimate gestational age and can lead to misclassification
of babies as born preterm, which has both short- and long-term clinical
care and public health implications.
OBJECTIVE: We sought to evaluate whether metabolic markers in
newborns measured as part of routine screening for treatable inborn errors
of metabolism can be used to develop a population-level metabolic
gestational dating algorithm that is robust despite intrauterine growth
restriction and can be used when fetal ultrasound dating is not available.
We focused specifically on the ability of these markers to differentiate
preterm births (PTBs) (<37 weeks) from term births and to assign a
specific gestational age in the PTB group.
STUDY DESIGN: We evaluated a cohort of 729,503 singleton new-
borns with a California birth in 2005 through 2011 who had routine
newborn metabolic screening and fetal ultrasound dating at 11e20
weeks’ gestation. Using training and testing subsets (divided in a ratio of
3:1) we evaluated the association among PTB, target newborn charac-
teristics, acylcarnitines, amino acids, thyroid-stimulating hormone, 17-
hydroxyprogesterone, and galactose-1-phosphate-uridyl-transferase. We
used multivariate backward stepwise regression to test for associationsCite this article as: Jelliffe-Pawlowski LL, Norton ME,
Baer RJ, et al. Gestational dating by metabolic profile at
birth: a California cohort study. Am J Obstet Gynecol
2016;214:511.e1-13.
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http://dx.doi.org/10.1016/j.ajog.2015.11.029assign a specific week of gestation. We used sensitivity, specificity, and
positive predictive value to evaluate the performance of linear functions.
RESULTS: Along with birthweight and infant age at test, we included 35
of the 51 metabolic markers measured in the final multivariate model
comparing PTBs and term births. Using a linear discriminate analyses-
derived linear function, we were able to sort PTBs and term births accu-
rately with sensitivities and specificities of 95% in both the training and
testing subsets. Assignment of a specific week of gestation in those
identified as PTBs resulted in the correct assignment of week2 weeks in
89.8% of all newborns in the training and 91.7% of those in the testing
subset. When PTB rates were modeled using the metabolic dating algo-
rithm compared to fetal ultrasound, PTB rates were 7.15% vs 6.11% in the
training subset and 7.31% vs 6.25% in the testing subset.
CONCLUSION: When considered in combination with birthweight and
hours of age at test, metabolic profile evaluated within 8 days of birth
appears to be a useful measure of PTB and, among those born preterm, of
specific week of gestation 2 weeks. Dating by metabolic profile may be
useful in instances where there is no fetal ultrasound due to lack of
availability or late entry into care.
Keywords: acylcarnitines, amino acids, galactose-1-phosphate-uridyl-
transferase, gestational dating, metabolic, metabolomics, preterm birth,
thyroid-stimulating hormone, 17-hydroxyprogesteroneIntroduction
Accurate gestational dating is a critical
component of obstetric and newborn
care. During pregnancy, gestational age
informs the scheduling and management
of clinical visits and laboratory testing,
determination of the appropriateness of
fetal growth, management and timing of
delivery, evaluation of the pregnancy as
being at risk for preterm and/or postterm
delivery, and the application of in-
terventions including, for example, theuse of antenatal corticosteroids and
magnesium for neuroprotection.1-4 In
the newborn period, gestational dating
informs critical decisions around resus-
citation (particularly in newborns born
around the limits of viability) and is
essential for tracking growth and neu-
rodevelopmental function.5,6
Accurate gestational dating is also
important for establishing population-
level rates of preterm birth (PTB).
Measuring and tracking this rate across
time is essential for establishing baselines
and for resource planning aimed at
reducing these outcomes and their
associated burden within and across
populations. While ﬁrst-trimester ultra-
sound is recognized as the best method
to establish gestational age for most
pregnancies, ultrasound dating becomes
less reliable as gestation progresses.7-18
Prenatal ultrasound dating is alsoAPRIL 2016 Ameriavailable only in sites with the resources
to purchase the equipment and hire
trained technicians. As such, prenatal
ultrasound is not available in some rural
and low- and middle-income country
settings.19
In the absence of early ultrasound,
many clinicians rely on last menstrual
period (LMP) for gestational dating. LMP
can be unreliable given that a number of
factors can inﬂuence dating including
poor recall, irregular cycle length, and
bleeding in early pregnancy.12,16,20,21
Symphysis-fundal height (SFH) >20
weeks is also used for pregnancy dating,
but is often inaccurate due to factors such
as multiple pregnancy, maternal size,
polyhydramnios and oligohydramnios,
and fetal growth restriction.19,22
When no other measures of gesta-
tional dating are available (eg, fetal ul-
trasound, LMP, SFH), other measurescan Journal of Obstetrics& Gynecology 511.e1
FIGURE
Sample selection
aResults present for 51 target markers and ra-
tios measured between 12 hours and 8 days
after birth as part of routine newborn screening.
GA, gestational age; PNS, prenatal screening.
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include the Dubowitz method (which
incorporates 34 physical and neurolog-
ical assessments),23,24 the Ballard
method (which uses 6 physical and
neurological measures taken within 30
and 42 hours of age),25 and the New
Ballard score (which uses an expanded
list of features over the original Ballard
method).26 While all of these measures
provide useful information when no
other data are available, like with use of
LMP and SFH, these methods have been
shown to be less accurate when there is
intrauterine growth restriction.27-29
The recognized need for a reliable
alternative gestational dating method in
instances where there is no ﬁrst- or
second-trimester ultrasound has led to an
increased focus on identifying new dating
methods and proxies that can be used
during pregnancy or at the time of birth.
Recent years have seen a punctuated effort
in this area with the initiation of a number
of high-risk, high-reward projects funded
through the Bill and Melinda Gates
Foundation30 and a recent call by the
National Institutes of Health for more
accurate tools to assess gestational age.31
In response to this call for newer dating
methods, in this study we hypothesized
that metabolic markers measured as part
of routine newborn screening for treat-
able inborn errors of metabolism could
be used to build a population-level
metabolic dating algorithm that is
robust despite intrauterine growth re-
striction. Speciﬁcally, we hypothesized
that when considered in combination
with newborn characteristics, metabolic
markers would be able to differentiate
PTBs (<37 weeks) from term births and
to assign a speciﬁc gestational agewithin a
margin of 2 weeks. If a metabolic dating
tool were developed, it could be used
broadly in high-income countries with
existing newborn screening programs
where no fetal ultrasound scan was done
and could also be used by researchers and
policy makers in other settings where
newborn specimens are available for
testing either retrospectively or prospec-
tively to establish population-level base-
line rates of PTB. Such a tool could
gain further acceptance in countries
without newborn screening through the511.e2 American Journal of Obstetrics& Gynecoluse of miniature or hand-held mass
spectrometers32 or via the translation of
ﬁndings into a clinical assay that does not
require the use of a mass spectrometer.
While our hypothesis that markers
used for newborn screening could also
be used for gestational dating purposes
is novel, the work is well supported
by previous studies demonstrating that
many of these routinely collected
markers (eg, acylcarnitines, amino acids,
thyroid-stimulating hormone [TSH])
are related to PTB and to week of gesta-
tion and have heritable components that
are robust in small-for-gestational-age
(SGA) infants.33-43 In the present study,
we developed and evaluated a metabolic
dating algorithm using a large and
diverse sample of California newborns
who had ultrasound dating between
11e20 weeks of gestation. We focused
speciﬁcally on the capacity of markers to
differentiate PTBs from term births and
to assign a speciﬁc gestational age in the
preterm group.
Materials and Methods
We evaluated whether biomarkers
collected as part of routine newborn
screening for treatable inborn errors of
metabolism could be used to create a
metabolic dating algorithm in a cohort
of 729,503 singleton newborns born in
California in 2005 through 2011. All of
these newborns had routine metabolic
screening performed through the Cali-
fornia Newborn Screening program us-
ing a heel-stick blood draw between 12
hours and 8 days after birth. All babies
had amother who had ultrasound dating
from 11e20 weeks of gestation, had a
linked birth certiﬁcate and hospital
discharge record, and were born at
22e44 completed weeks of gestation
(sample selection included in Figure).
For study purposes, we randomly
divided the ﬁnal cohort into a training
subset with 547,127 babies (75% of to-
tal) and a testing subset with 182,376
babies (25% of total). This division
allowed for an unbiased estimate of
model performance given that the
testing set was not part of the sample in
which the initial model was built.
Date of birth, birthweight, gender,
and race/ethnicity were derived from theogy APRIL 2016birth cohort ﬁles, which are linked birth
certiﬁcate and hospital discharge ﬁles
obtained from the California Ofﬁce of
Statewide Health Planning and Devel-
opment. Age at testing in hours after
birth, blood-spot analyte measure-
ments, and information about whether
the infant had been on total parenteral
nutrition (TPN) between birth and the
time of testing was obtained from
newborn screening records. We were
able to identify newborns with fetal ul-
trasound dating from 11e20 weeks of
gestation by examining linked newborn
and prenatal screening records. We
computed days of gestation at birth by
comparing the estimated date of de-
livery based on ultrasound ﬁndings in
the prenatal screening records to the
birth date on the linked birth certiﬁcate
and hospital discharge records. In Cali-
fornia, the prenatal and newborn
TABLE 1
Newborn characteristics
n ¼ a %
Sample 729,503 100.0
Race/ethnicity
White, not
Hispanic
233,729 32.0
Hispanic 343,388 47.1
Asian 90,219 12.4
Black 25,814 3.5
Other 36,307 5.0
Gender
Male 372,689 51.1
Female 354,189 48.6
Completed gestation,
wkb
<32 3809 0.5
32e36 41,014 5.6
37 684,680 93.9
Weight for gestational
agec
<10th (SGA) 51,469 7.1
10e90th (AGA) 617,147 84.6
>90th (LGA) 60,887 8.4
H/d at testing
12e24 h 262,323 36.0
2e3 d 397,301 54.5
4e5 d 51,076 7.0
7e8 d 18,803 2.6
Total parenteral
nutrition
10,264 1.4
AGA, appropriate-for-gestational age; LGA, large-for-
gestational age; SGA, small-for-gestational age.
a Value missing where sum for category does not equal
total sample size; b Based on 11e20 wk fetal ultra-
sound; c Using Alexander et al.48
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the same division of the California
Department of Public Health (the Ge-
netic Disease Screening Program). This
nesting allows for routine linkage of
prenatal and newborn screening re-
cords. The prenatal and newborn
screening data used in this study were
obtained from the California Biobank
Program. Details regarding the Califor-
nia Newborn Screening Program and
the California Prenatal Screening Pro-
gram have been described in detail
elsewhere.44,45
All markers evaluated in the study
were tested by the California Depart-
ment of Public Health’s Genetic Disease
Laboratory as part of routine screening
for treatable inborn errors of meta-
bolism using dried blood specimens
collected by heel-stick at birth hospitals
from 12 hours to 8 days after birth.
Free carnitine, acylcarnitines (C-2, C-3,
C-3DC, C-4, C-5, C-5:1, C-5DC, C-6,
C-8, C-8:1, C-10, C-10:1, C-12, C-12:1,
C-14, C-14:1, C-16, C-16:1, C-18,
C-18:1, C-18:2, C-18:1OH), and amino
acids (alanine, arginine, citrulline,
glycine, methionine, ornithine, phenyl-
alanine, proline, 5-oxoproline, tyrosine,
valine) were measured by standardized
tandem mass spectrometry. TSH
and 17-hydroxyprogesterone (17-OHP)
were measured using high-performance
liquid chromatography. Galactose-
1-phosphate-uridyl-transferase was
measured using a ﬂuorometric enzyme
assay. The study also utilized a number
of ratios commonly used in screening
(C-14:1/C-12:1, C-1/C-2, C-8/C-10, free
carnitine/(C-16 þ C-18:1), arginine/
ornithine, citrulline/arginine, leucine/
alanine, leucine/isoleucine, ornithine/
citrulline, and phenylalanine/tyrosine).
We transformed biomarker values and
ratios using natural logarithms
to normalize distribution across all
markers.
Analyses ﬁrst focused on evaluating
the association among maternal charac-
teristics, markers, and PTB in the
training subset using simple bivariate
logistic regression and related odds ra-
tios and 95% conﬁdence intervals (CI).
We used multivariate backward stepwise
regression for ﬁnal model building withentry at P < .40 based on bivariate ana-
lyses and removal at P < .05. TPN was
included in multivariate models regard-
less of observed P values given the
demonstrated relationship between TPN
and some markers tested as part of
routine screening (eg, some acylcarni-
tines and amino acids)40,41,46,47 and our
desire to identify markers with a robust
association with gestational age despite
TPN status. Characteristics and markers
remaining in the ﬁnal TPN-adjusted
multivariate model were used to create
a linear discriminate analysis (LDA)-
derived linear function that we used to
sort PTBs and term births. Markers were
also leveraged to create an LDA-derived
linear function for speciﬁc week of
gestation in those identiﬁed as preterm.
We evaluated the performance of the
linear functions in both the training and
testing subsets using sensitivity, speci-
ﬁcity, and positive predictive values
(PPVs) and their 95% CIs. We evaluated
performance in all births and in subsets
grouped as SGA (<10th percentile
weight for gestational age), appropriate
for gestational age (10the90th percentile
weight for gestational age), and large for
gestational age (>90th percentile weight
for gestational age) based on published
US norms.48 Week-speciﬁc LDA-derived
linear functions were evaluated by their
capacity to assign week of gestation in
those identiﬁed as preterm compared to
ultrasound-dated week. We further
examined the modeled rates of
PTB based on the metabolic dating al-
gorithm compared to ultrasound-dated
week.
We performed all analyses using soft-
ware (SAS, Version 9.3; SAS Institute Inc,
Cary, NC). Methods and protocols for
the study were approved by the Com-
mittee for the Protection of Human
Subjects within the Health and Human
Services Agency of the State of California
(protocol no. 12-09-0702).
Results
The study cohort included 729,503
singleton infants (20.2% of the total
population of singletons in these birth
years [n ¼ 3,617,727]). This number
represented those with ultrasound re-
sults and linked birth and hospitalAPRIL 2016 Ameridischarge records who had gestational
age from 22e44 weeks (Figure). Race/
ethnicity and gender was similar to that
of all births during this time period49
wherein most newborns were Hispanic
(47.1%) or non-Hispanic white (32.0%)
with more male than female births
(51.1% vs 48.6%). Nine in 10 newborns
had newborn screening conducted
within 3 days (Table 1).can Journal of Obstetrics& Gynecology 511.e3
TABLE 2
Markers and characteristics in final <37 weeks’ modela
AdjOR 95% CI
Acylcarnitines
C-3 3.526 3.344e3.719
C-3DC 0.750 0.706e0.798
C-4 1.054 1.017e1.093
C-5 1.918 1.845e1.995
C-5:1 1.032 1.014e1.051
C-5DC 1.972 1.868e2.082
C-6 0.930 0.911e0.950
C-8:1 1.083 1.053e1.115
C-10 0.860 0.829e0.893
C-12 0.835 0.802e0.870
C-12:1 0.589 0.524e0.662
C-14 1.394 1.312e1.481
C-14:1 1.427 1.245e1.635
C16:1 1.160 1.097e1.226
C-18 1.383 1.279e1.496
C-18:1 1.692 1.527e1.876
C-18:2 1.192 1.143e1.243
Free carnitine 0.146 0.127e0.168
C-14:1/C-12:1 0.805 0.722e0.897
Free carnitine/(C-16 þ C-18:1) 0.146 0.127e0.168
Amino acids
Alanine 0.135 0.126e0.144
Glycine 1.399 1.299e1.508
Methionine 1.291 1.205e1.384
Ornithine 0.263 0.243e0.284
Proline 0.889 0.832e0.949
Tyrosine 7.940 7.128e8.845
Valine 0.566 0.525e0.611
5-Oxoproline 1.144 1.108e1.181
Leucine/isoleucine 3.020 2.729e3.342
Citrulline/arginine 0.849 0.827e0.873
Phenylalanine/tyrosine 2.235 2.022e2.470
Ornithine/citrulline 2.137 2.002e2.470
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acteristics, 49 of the 51 metabolites and
metabolite ratios measured were associ-
ated with PTB in crude logistic regres-
sion analyses (all except C-5DC and
C-18) (Supplementary Table 1). Male511.e4 American Journal of Obstetrics& Gynecolgender, race/ethnicity, and 14 metabolic
markers were removed from ﬁnal
multivariate logistic models using step-
wise methods given P values >.05. Hour
of age at collection, birthweight, and 35
metabolic markers were included in theogy APRIL 2016ﬁnal multivariate logistic regression
model (Table 2). When a LDA-derived
linear function was built based on these
training set multivariate logistic results,
we found that these characteristics and
markers were able to identify PTBs with
>95% accuracy in the training and
testing subsets (sensitivity 99.5% [95%
CI, 99.5e99.6%], speciﬁcity 98.8%
[95% CI, 98.8e98.9%] in the training
subset; sensitivity 99.5% [95% CI,
99.4e99.6%], speciﬁcity 98.9% [95%
CI, 98.8e98.9%] in the testing subset).
Findings were robust across SGA,
appropriate-for-gestational-age, and
large-for-gestational-age babies (sensi-
tivity and speciﬁcity across all groups
94.9%). PPVs tended to be >85%
across most groupings with the excep-
tion of the SGA group where PPVs were
>66% (66.0% [95% CI, 64.6e67.2%] in
the training set, 66.7% [95% CI,
64.4e68.9%] in the testing subset)
(Table 3). Assignment of a speciﬁc week
of gestation in those identiﬁed as pre-
term resulted in the correct assignment
2 weeks in 89.8% of all newborns in
the training set and 91.7% of newborns
in the testing subset (Table 4).
Our ﬁnal metabolic dating algorithm
relied ﬁrst on sorting PTBs and term
births using the LDA-derived linear
function in Supplementary Table 2, and
then, assigning weeks of gestation to
those identiﬁed as preterm using the
linear function in Supplementary
Tables 3 and 4. When this algorithm
was tested against prenatal ultrasound at
11e20 weeks, we found that it calculated
the incidence of PTB <37 weeks as
7.15% vs 6.11% in the training set and
7.31% vs 6.25% in the testing subset, the
rate of PTB <32 weeks as 0.71% vs
0.53% in the training set and 0.71% vs
0.51% in the testing subset, and PTB
32e36 weeks as 6.44% vs 5.58% in the
training set and 6.60% vs 5.74% in the
testing subset (Table 5).
Comment
Using birthweight, age at testing, and
a number of the markers measured as
part of routine newborn screening
for treatable inborn errors of meta-
bolism within 8 days of life (acylcarni-
tines, amino acids, TSH, 17-OHP, and
TABLE 2
Markers and characteristics in final <37 weeks’ modela (continued)
AdjOR 95% CI
Other
Thyroid-stimulating hormone 0.810 0.788e0.832
17-OHP 2.963 2.879e3.048
GALT 0.552 0.513e0.593
Birthweightb 0.997 0.997e0.997
Hour at testb 1.025 1.024e1.027
AdjOR, adjusted odds ratio; CI, confidence interval; FC, free carnitine; GALT, galactose-1-phosphate-uridyl-transferase;
17-OHP, 17-hydroxyprogesterone.
a All variables natural log-transformed, associations P < .01 after adjustment for all other markers in model and for total
parenteral nutrition; b Included as continuous variable.
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we were able to build a metabolic dating
algorithm that was able to consistently
sort PTBs from term births with
approximately 95% sensitivity and
speciﬁcity. Among newborns identiﬁed
as preterm, we were able to assign a
gestational week that was within 2 weeks
of gestational age determined by ultra-
sound in about 90% of cases. PTB rates
using metabolic dating were within a
range of about 1% of those generated
using ultrasound.
While no other published study that
we are aware of has used the combina-
tion of these markers for gestationalTABLE 3
Performance of linear discriminate for
Training
Sensitivity (95% CI) Specificity (
All 99.5% 98.9%
(99.5e99.6) (98.8e98.9)
SGAa 99.9 95.1
(99.8e100.0) (94.8e95.3)
AGAa 99.6 99.1
(99.5e99.7) (99.1e99.1)
LGAa 95.4 99.7
(94.1e96.6) (99.7e99.8)
AGA, appropriate (birthweight 10e90th percentile) for gestationa
(birthweight <10th percentile) for gestational age.
a Based on Alexander et al.48
Jelliffe-Pawlowski et al. Dating by metabolic proﬁle: Californdating, our ﬁndings are in agreement
with other studies that have demon-
strated an association between PTB
and many of the individual biomarkers
studied including those that have
found that differences remain after
accounting for SGA and feeding
status.33-43 Like other investigators we
observed signiﬁcant differences between
PTBs and term births in free carnitine33,39;
short-, medium-, and long-chain acyl-
carnitines33,39-41,43; amnio acids39-41,43;
TSH35,37,50; and 17-OHP.47,51,52 Although
it is unclear what speciﬁcally underlies
the differences observed and why they
appear useful for gestational dating, it<37 completed weeks’ gestation
Testing
95% CI) PPV (95% CI) Sensitivity (95% CI)
85.1% 99.5%
(84.7e85.4) (99.4e99.6)
66.0 100.0
(64.6e67.2) (99.6e100.0)
87.9 99.6
(87.5e88.2) (99.5e99.7)
89.3 94.9
(87.4e90.9) (92.0e96.9)
l age; CI, confidence interval; LGA, large (birthweight>90th percentile)
ia. Am J Obstet Gynecol 2016.
APRIL 2016 Ameriappears that both etiological and
maturational underpinnings may exist
that are marker speciﬁc. For instance,
2 of the acylcarnitines (C-8:1 and
C-18:2) included in the ﬁnal predictive
model have been shown to be associated
with maternal preeclampsia in studies
that have examined maternal serum
during pregnancy and newborn blood-
spots.47,53 Reasons for these associations
have been hypothesized as being related
to abnormalities in fatty acid oxidation
in the mother, the baby, or both
suggesting an etiological link. While
other work has found that C-8:1 and
C-18:2 are not as closely tied to speciﬁc
gestational age among those born pre-
term, other acylcarnitines in our ﬁnal
model including C-4, C-5, and C-6
are.34 This latter pattern suggests that
these marker patterns may be more
closely tied to maturation. Similar sus-
pected links to fatty acid metabolism
and maturation have been discussed at
length with respect to other acylcarni-
tines and amino acids included in
our ﬁnal model as well as TSH and
17-OHP.36,38,40-42,44,51,52
For the most part, studies that have
evaluated methods of dating absent ul-
trasound have focused on LMP and SFH
during pregnancy12,16,19-22 and the
Dubowitz, Ballard, and the New Ballard
methods at birth.23-26 In general, all ofSpecificity (95% CI) PPV (95% CI)
98.8% 85.2%
(98.8e98.9) (84.6e85.8)
95.0 66.7
(94.6e95.4) (64.4e68.9)
99.1 87.9
(99.0e99.1) (87.2e88.5)
99.7 89.4
(99.6e99.8) (85.8e92.2)
for gestational age; PPV, positive predictive value; SGA, small
can Journal of Obstetrics& Gynecology 511.e5
TABLE 4
Estimate of week of gestation using metabolic-based algorithm in those identified as preterma
Training Testing
 1 wk (95% CI) 2 wk (95% CI) 3 wk (95% CI) 1 wk (95% CI) 2 wk (95% CI) 3 wk (95% CI)
<37 wk 78.8% 89.8% 95.4% 78.3% 91.7% 96.3%
(78.4e79.2) (89.5e90.1) (95.2e95.6) (77.6e79.0) (80.7e91.7) (96.0e96.6)
<32 wk 52.1 72.6 81.7 53.1 73.7 84.9
(50.3e53.9) (71.1e74.3) (80.3e83.1) (49.9e56.3) (70.9e76.6) (82.6e87.2)
32e36 wk 80.9 91.2 96.5 80.2 92.5 97.2
(80.5e81.3) (90.9e91.5) (96.3e96.7) (795e80.9) (92.0e92.9) (96.9e97.5)
CI, confidence interval.
a Where algorithm used linear discriminate for<37 wk (supplementary Table 1) and then, among those positive for<37 wk, used week-specific linear discriminate (Supplementary Tables 2 and 3).
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approximating gestational age, often for
seemingly different reasons.With LMP it
appears that there is a tendency to date a
pregnancy later, which then leads to a
greater tendency to label a birth as being
preterm54; with SFH, the Dubowitz, and
the older and New Ballard methods,
underestimates often result and appear
to be more closely tied to problems with
dating when there is intrauterine growth
restriction.19,22,27-29 For example, in a
recent study of all US birth certiﬁcates
from 2012, Duryea and colleagues54
found that use of LMP instead of
ultrasound-derived best obstetric esti-
mate led to an overall overestimate in theTABLE 5
Estimate of population-level preterm b
algorithma
Training
Modeled, %
(95% CI)
Fetal ultrasound
(95% CI)
<37 wk 7.15 6.11
(7.08e7.22) (6.05e6.17)
<32 wk 0.71 0.53
(0.69e0.73) (0.51e0.53)
32e36 wk 6.44 5.58
(6.37e6.51) (5.52e5.64)
CI, confidence interval.
a Where algorithm used linear discriminate for <37 wk (Supplem
used week-specific linear discriminate (Supplementary Tables
Jelliffe-Pawlowski et al. Dating by metabolic proﬁle: Californ
511.e6 American Journal of Obstetrics& Gynecolnational PTB rate of >1.9% and over-
estimates of PTB rates in teenagers and
non-Hispanic blacks of >3%. With
respect to use of the Dubowitz, Ballard,
and the new Ballard, studies have found
that these measures tend to perform
particularly poorly in babies born pre-
term with agreement with ultrasound
2 weeks of as little as 55%.27-29
The metabolic dating algorithm pre-
sented here appears to represent an
improvement over dating by LMP, SFH,
Dubowitz, Ballard, or the New Ballard
given that it was able to identify babies
born preterm with >99% sensitivity
and speciﬁcity and had associated PTB
rates that were within 1% of thoseirth rates using metabolic-based
Testing
, % Modeled, %
(95% CI)
Fetal ultrasound, %
(95% CI)
7.31 6.25
(7.19e7.43) (6.14e6.36)
0.71 0.51
(0.67e0.75) (0.48e0.54)
6.60 5.74
(6.49e6.71) (5.63e5.85)
entary Table 1) and then, among those positive for <37 wk,
2 and 3).
ia. Am J Obstet Gynecol 2016.
ogy APRIL 2016determined using ultrasound measures.
Further support for this assessment is
demonstrated by its capacity to assign
gestational age within 2 weeks in 90% of
those identiﬁed as preterm. Such ﬁnd-
ings require careful replication, and it
should be noted that even with replica-
tion, it is unclear how metabolic dating
might be used. In the United States and
developed countries, there would likely
be opportunity to leverage these data in
instances where ultrasound dating was
not done given routine testing of these
markers. Where the testing of the
markers is already being done as part of
routine newborn screening for treatable
inborn errors of metabolism, translation
could be accomplished, for example, at
hospitals or clinics through an online
application. It is also possible that this
algorithm could be run routinely for all
newborns through partnership with
newborn screening programs. In lower
resource settings where routine mea-
surement is not done and where mass
spectrometry technology is often not
available, use of this algorithm might be
more aptly used for retrospective base-
lining of PTB rates using banked serum
specimens. Use of miniature or hand-
held mass spectrometers32 or trans-
lation of ﬁndings into a clinical assay
that does not require mass spectrometry
could potentially lead to wider pro-
spective use in those settings if the al-
gorithms were found to replicate.
Important strengths of the present
study include the use of a large and
ajog.org OBSTETRICS Original Researchdiverse sample of newborns who had
fetal ultrasound dating from 11-20
weeks. Analyses also beneﬁted from the
availability of birthweight and gesta-
tional age, which allowed for the evalu-
ation of performance in the face of
intrauterine growth restriction. Both of
these strengths should be considered in
tandem with limitations. For example,
while our sample was representative of
the diverse race/ethnic makeup of all
California births, it is possible that other
factors like poverty, nutrition, and access
to care could have affected access to an
early ultrasound. Further follow-up in
target populations is essential to assess
performance. With respect to the
strength of being able to look at patterns
among the SGA group, it is important to
note that while sensitivities and speci-
ﬁcities were >95% across training and
testing subsets, PPVs were around
66.0%. This ﬁnding means that about
33% of SGA term babies were wrongly
coded as preterm when in fact they were
term. This ﬁnding lends further support
to the need for replication and suggests a
need to work toward even better
performance.
Conclusion
In combination with birthweight and
hours of age at test, metabolic proﬁle
evaluated within 8 days of birth appears
to be a useful measure of PTB and,
among those born preterm, of speciﬁc
week of gestation 2 weeks. Dating by
metabolic proﬁle may be useful in in-
stances where there is no dating by pre-
natal ultrasound due to lack of
availability or late entry into obstetric
care. n
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SUPPLEMENTARY TABLE 1
Logistic regression: crude results, risk of preterm birth by specific bivariate target categorical variables and by
per-natural log unit increase in target continuous variables
OR 95% CI P value
Total parenteral nutritiona 1.000 1.000e1.000 .326
Male gendera 1.215 1.188e1.243 <.001
Race/ethnicitya
White 0.982 0.960e1.005 .129
Hispanic 1.241 1.213e1.268 <.001
Black 1.134 1.072e1.201 <.001
Asian 0.925 0.894e0.958 <.001
Other 1.046 1.019e1.074 <.001
Hour at collectionb 1.032 1.031e1.032 <.001
Birthweightb 0.997 0.997e0.997 <.001
Metabolitesb
FC 2.193 2.137e2.251 <.001
Acylcarnitines
C-2 1.183 1.143e1.225 <.001
C-3 3.024 2.939e3.111 <.001
C-3DC 0.650 0.631e0.669 <.001
C-4 2.369 2.312e2.428 <.001
C-5 7.709 7.509e7.914 <.001
C-5:1 1.162 1.146e1.178 <.001
C-5DC 1.011 0.987e1.035 .3858
C-5OH 1.223 1.193e1.254 <.001
C-6 0.966 0.951e0.981 <.001
C-8 1.140 1.120e1.161 <.001
C-8:1 1.424 1.393e1.456 <.001
C-10 0.686 0.672e0.702 <.001
C-10:1 1.343 1.317e1.370 <.001
C-12 0.632 0.620e0.645 <.001
C-12:1 0.556 0.546e0.566 <.001
C-14 0.862 0.837e0.889 <.001
C-14:1 0.797 0.780e0.815 <.001
C-14OH 0.851 0.839e0.863 <.001
C-16 0.296 0.287e0.306 <.001
C-16:1 0.506 0.495e0.518 <.001
C-16OH 0.831 0.819e0.843 <.001
C-18 0.974 0.942e1.006 .106
C-18OH 0.905 0.890e0.915 <.001
C-18:1 1.112 1.073e1.151 <.001
C-18:1OH 0.902 0.890e0.915 <.001
C-18:2 4.743 4.635e4.853 <.001
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SUPPLEMENTARY TABLE 1
Logistic regression: crude results, risk of preterm birth by specific bivariate target categorical variables and by
per-natural log unit increase in target continuous variables (continued)
OR 95% CI P value
C-14:1/C-12:1 1.799 1.761e1.838 <.001
C-1/C-2 3.323 3.219e3.429 <.001
C-8/C-10 1.202 1.185e1.219 <.001
FC/(C-16 þ C-18:1) 3.144 3.067e3.223 <.001
Amino acids
Alanine 0.424 0.408e0.440 <.001
Arginine 1.748 1.718e1.778 <.001
Citrulline 0.385 0.370e0.401 <.001
Glycine 0.436 0.417e0.456 <.001
Methionine 3.827 3.687e3.973 <.001
Ornithine 1.427 1.381e1.475 <.001
Phenylalanine 4.720 4.491e4.961 <.001
Proline 1.366 1.317e1.417 <.001
5-Oxoproline 0.949 0.933e0.965 <.001
Tyrosine 3.959 3.844e4.077 <.001
Valine 2.547 2.455e2.643 <.001
Arginine/ornithine 1.609 1.580e1.638 <.001
Citrulline/arginine 0.467 0.459e0.476 <.001
Phenylalanine/tyrosine 0.444 0.431e0.457 <.001
Leucine/arginine 11.787 11.359e12.232 <.001
Ornithine/citrulline 2.441 2.366e2.518 <.001
Leucine/isoleucine 8.077 7.770e8.395 <.001
Other markers
TSH 0.496 0.489e0.504 <.001
17-OHP 3.888 3.814e3.964 <.001
GALT 0.479 0.457e0.501 <.001
CI, confidence interval; FC, free carnitine; GALT, galactose-1-phosphate-uridyl-transferase; OR, odds ratio; TSH, thyroid-stimulating hormone; 17-OHP, 17-hydroxyprogesterone.
a Yes vs no; b Considered as continuous variable.
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SUPPLEMENTARY TABLE 2
Linear discriminate for <37 weeks including markers and characteristics in
final multivariate model (Table 2)a
Constant e1638
Alanine e18.24294
C-3 e10.58859
C-3DC e37.34471
C-4 e3.91865
C-5 e7.79132
C-5:1 e4.97254
C-5DC 17.50509
C-6 e4.04150
C-8:1 e1.83483
C-10 e5.82510
C-12 e18.94594
C-12:1 e3.1822
C-14 e23.82009
C-14:1 e0.74261
C-16:1 e38.39710
C-18 e12.85971
C-18:1 e35.36104
C-18:2 e15.45137
FC 110.08731
Glycine 77.65724
Methionine e8.43507
17-Hydroxyprogesterone 25.70541
Ornithine e30.59164
5-Oxoproline e5.62405
Proline 19.81972
C-14/C-12 0.98818
Citrulline/arginine 7.26629
FC/(C-16 þ C-18:1) e77.59400
Phenylalanine/tyrosine 48.51520
Ornithine/citrulline 10.20481
Galactose-1-phosphate-uridyl-transferase 125.71008
Thyroid-stimulating hormone 4.45184
Tyrosine 100.77265
Valine e15.02337
Leucine/isoleucine 56.81949
Birthweight e0.01154
Hour at collection 0.87703
FC, free carnitine.
a All markers and characteristics natural log transformed.
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SUPPLEMENTARY TABLE 3
Linear discriminate for week of gestation among those <37 weeks based on <37 discriminate (weeks 22e29)a
22 23 24 25 26 27 28 29
Constant e932.50675 e953.2113 e944.19404 e948.56204 e955.93217 e959.50151 e976.27912 e982.90321
Alanine 8.28894 5.19942 5.113 4.62529 3.86256 4.22772 3.7845 3.93171
C-3 e16.57929 e18.46201 e17.87288 e17.76792 e17.71771 e17.82173 e17.44024 e17.698
C-3DC e26.19027 e24.67952 e23.93584 e24.53703 e26.23626 e25.96805 e27.12178 e26.73299
C-4 e3.49777 e3.32801 e3.45246 e3.4786 e3.83773 e4.18724 e4.30985 e4.54618
C-5 e15.17012 e13.27513 e13.4379 e13.80958 e14.44197 e14.52518 e14.7515 e14.9885
C-5:1 e5.20145 e5.50342 e5.37255 e5.30278 e5.28731 e5.23548 e5.30954 e5.31411
C-5DC 8.61735 9.44106 9.35617 8.93827 9.2908 9.03588 9.6062 9.33133
C-6 e2.43769 e2.70927 e2.31853 e2.54648 e2.43333 e2.56419 e2.71891 e2.56632
C-8:1 e3.54416 e1.30691 e1.27859 e1.14956 e0.99902 e0.95415 e1.00536 e1.03539
C-10 e1.45075 e2.32381 e2.89901 e2.61843 e2.98864 e3.22778 e2.67265 e3.04453
C-12 e9.83389 e11.16881 e10.79162 e10.86977 e10.82765 e10.98124 e10.68184 e10.84405
C-12:1 e4.30408 e5.17368 e3.18408 e3.42082 e3.72526 e3.50739 e4.70966 e3.58627
C-14 e24.11108 e25.88159 e25.01019 e25.02206 e24.87757 e24.51515 e25.50242 e24.42464
C-14:1 6.93662 7.6508 5.2393 5.49597 6.31254 6.28035 7.70797 6.18614
C-16:1 e28.26956 e30.04201 e29.88644 e29.83031 e30.38756 e30.03092 e30.85866 e30.87226
C-18 e19.04334 e18.99306 e19.29755 e19.47758 e19.59952 e19.75949 e20.23575 e20.90977
C-18:1 e27.08947 e27.34848 e26.73875 e28.0138 e28.65903 e29.87428 e31.29109 e31.51176
C-18:2 e18.23344 e19.76523 e18.9327 e18.91284 e18.17538 e17.52888 e17.2471 e17.61357
FC 103.89573 110.25176 108.33635 110.84605 112.29876 113.22328 115.79517 117.10496
Glycine 64.78615 64.88581 64.06058 63.84417 64.26949 64.10494 64.27953 63.82198
Methionine e27.9073 e24.10761 e23.41544 e24.82403 e24.14709 e24.0655 e23.77045 e23.05988
17-OHP 15.15918 15.89029 15.72505 15.39154 15.08971 14.81963 14.37009 14.15223
Ornithine e21.02409 e20.63325 e19.16193 e18.51997 e18.09949 e18.38862 e18.35503 e18.47604
5-Oxoproline e6.63031 e5.98036 e5.86063 e5.8677 e6.00961 e6.21009 e5.92026 e5.94451
Proline 13.25993 15.82941 15.36645 15.05716 15.88264 15.73205 15.9093 15.95879
C-14/C-12 e2.53122 e2.94236 e1.96468 e2.14515 e3.04039 e2.54535 e3.80081 e2.57918
Citrulline/arginine 11.59236 11.65395 11.79839 11.48146 11.66921 11.74594 11.6364 11.85715
FC/(C-16 þ C-18:1) e64.34898 e70.50515 e68.60503 e70.80802 e73.21485 e74.42308 e77.05317 e78.49802
Phenylalanine/tyrosine 29.38101 30.9779 30.30119 31.74303 32.59037 32.31711 33.66762 33.54525
Ornithine/citrulline 7.4646 5.17964 4.93853 4.94507 5.90052 6.37034 6.96901 7.54495
GALT 105.89469 106.88822 107.56674 107.74282 108.86221 109.89883 111.26397 112.24477
TSH 1.91686 1.15133 1.02702 1.31333 2.05631 2.44641 3.115 3.45602
Tyrosine 55.10445 57.34291 56.23898 57.21708 57.63742 56.9794 58.07309 57.79313
Valine 3.69641 2.35564 2.57893 2.91362 1.85609 1.83322 1.37229 1.6306
Leucine/isoleucine 42.61538 40.77523 40.2314 40.59463 39.63484 40.17964 39.87732 39.60262
Birthweight 0.0079 0.00755 0.0081 0.00791 0.0088 0.00932 0.00976 0.01033
Hour at collection 0.26349 0.29616 0.2839 0.28964 0.30761 0.31524 0.33132 0.33422
FC, free carnitine; GALT, galactose-1-phosphate-uridyl-transferase; TSH, thyroid-stimulating hormone; 17-OHP, 17-hydroxyprogesterone.
a All markers and characteristicsnatural log transformed.
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SUPPLEMENTARY TABLE 4
Linear discriminate for week of gestation among those <37 weeks based on <37 discriminate (weeks 30e36)a
30 31 32 33 34 35 36
Constant e988.50527 e995.75501 e1002 e1002 e998.81947 e996.26659 e999.34745
Alanine 4.2087 4.63183 5.28633 5.69558 6.14229 6.20216 6.44306
C-3 e17.60178 e17.7607 e17.77486 e17.69336 e17.76725 e18.13269 e18.62529
C-3DC e27.68125 e28.25113 e28.9111 e29.53141 e29.88425 e29.73349 e29.39607
C-4 e4.55088 e4.7859 e4.83465 e4.98735 e5.0364 e5.05325 e5.07372
C-5 e15.09459 e15.19294 e15.34302 e15.54043 e15.88192 e16.02557 e16.2285
C-5:1 e5.35522 e5.42657 e5.44484 e5.46036 e5.51482 e5.55429 e5.5616
C-5DC 9.56253 9.27383 9.35232 9.76537 9.93317 9.92958 9.67189
C-6 e2.69388 e2.59329 e2.58995 e2.47167 e2.5003 e2.52172 e2.49855
C-8:1 e0.73882 e0.68425 e0.83416 e0.53371 e0.32432 e0.23999 e0.31901
C-10 e3.03439 e2.51854 e2.42259 e2.2638 e2.10738 e2.06029 e1.98061
C-12 e10.74325 e10.55858 e10.52381 e10.31629 e10.06991 e9.68766 e9.58632
C-12:1 e2.82098 e2.41691 e2.5843 e2.1284 e2.3772 e2.377 e2.19121
C-14 e24.35735 e23.68109 e23.44333 e23.23374 e23.24398 e23.37978 e23.54099
C-14:1 5.64052 4.48174 4.57604 3.82457 4.35081 4.89146 4.90526
C-16:1 e30.9545 e30.99005 e31.26494 e31.30972 e31.66705 e31.83462 e31.95655
C-18 e21.113 e21.37849 e21.61745 e22.16167 e22.88771 e23.13368 e23.03947
C-18:1 e31.58447 e32.71608 e32.61122 e32.51187 e31.55139 e31.52162 e31.83863
C-18:2 e17.28389 e17.43331 e17.59197 e17.57429 e17.87897 e17.89621 e17.89402
FC 117.35909 118.973 119.32926 119.78986 120.27383 120.61386 121.04239
Glycine 64.02354 63.93202 63.79536 63.68921 63.68449 63.92172 63.82196
Methionine e23.72761 e23.35167 e23.21117 e23.02348 e22.96024 e22.85355 e22.81308
17-OHP 13.56281 13.24651 13.18203 13.05065 12.83415 12.50796 12.24516
Ornithine e18.95869 e18.73249 e18.87447 e19.29801 e19.63549 e19.22495 e18.6176
5-Oxoproline e6.05998 e6.02286 e6.10127 e5.89173 e5.96226 e5.97521 e5.95991
Proline 16.44024 16.18929 16.42513 16.9491 17.23069 17.42308 17.438
C-14/C-12 e2.14244 e1.57293 e1.70284 e1.41461 e1.60313 e1.86508 e1.86071
Citrulline/arginine 11.94376 12.07144 12.26846 12.53041 12.67593 12.7734 12.76036
FC/(C-16 þ C-18:1) e78.71474 e80.49481 e81.17256 e81.80405 e82.61718 e83.21782 e83.7118
Phenylalanine/tyrosine 34.56247 34.40066 33.90638 32.9183 32.63234 32.02879 31.70916
Ornithine/citrulline 8.34688 8.36896 8.79664 9.27236 9.64076 9.55739 9.27991
GALT 113.10771 113.38068 113.72742 113.67361 113.26317 113.05344 113.38014
TSH 3.58492 3.80202 3.95464 4.09603 4.33518 4.48642 4.56842
Tyrosine 58.82914 59.05708 58.79186 58.10647 57.76591 56.9272 56.30401
Valine 1.05805 0.91155 0.86614 0.63452 0.60383 0.52097 0.6643
Leucine/isoleucine 39.02383 38.99794 38.58841 38.14015 37.45876 37.2543 37.01122
Birthweight 0.0113 0.01203 0.01267 0.01367 0.01446 0.01535 0.01631
Age at collection 0.33723 0.33865 0.34199 0.34225 0.33639 0.32541 0.31429
FC, free carnitine; GALT, galactose-1-phosphate-uridyl-transferase; TSH, thyroid-stimulating hormone; 17-OHP, 17-hydroxyprogesterone.
a All markers and characteristics natural log transformed.
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